Pending Transformation After a €16 Million Investment

PRESS RELEASE ATTACHMENT

Since our founding in 2017 by our CEO, Athanase Kollias, Kinvent has become the European leader in connected physiotherapy solutions. What started as a focus on the design, development, and manufacture of a range of connected sensors that instantly measure force, balance, and range of motion, has become a revolution in physiotherapy, providing a single application for the sports performance, rehabilitation, and medical industries. 

We are proud to say that our groundbreaking solutions have brought measurable, objective data into physiotherapy, and in doing so, increased patient engagement, ensuring better continuity of care, and enabling the implementation of personalized rehabilitation programs. As a result of these monumental achievements in physiotherapy innovation, we have experienced a rapid expansion since our inception. 

[Read the LinkedIn Publication]

Kinvent’s Remarkable Journey: From 80% Growth to International Expansion

Despite a still poorly connected market, Kinvent recorded an 80% growth between 2022 and 2023. Since then, our 8 sensors, which cover the majority of tests performed in physiotherapy sessions, have attracted more than 14,000 rehabilitation professionals (sports specialists, general practitioners, or those working in nursing homes or post-surgical units), healthcare professionals, and even professional sports clubs, spread across 68 countries. This swift popularity allowed us to boost our acclaim internationally through partnerships with such renowned clubs as Montpellier Hérault Rugby, the French Athletics Federation, and the New York Mets. 

Throughout this time, we were able to fuel our success through two rounds of funding that have led us to the pivotal moment we have reached today. In 2019 we received €1M, which kick started our journey, then once we were more established we received €6M in funding in 2021. After these wins, we are deeply proud to announce that as a result of a highly successful round of fundraising, we are entering in a new era. The jaw-dropping total from our 3rd round of fundraising: €16M, will allow us to usher in a new acceleration phase to penetrate the U.S. market, accelerate our research and external growth activities. Pending this exceptional transformation, we are now setting out to conquer the global connected physiotherapy device market with our new partners, French private equity firm Eurazeo, at our side.

 

Eurazeo Joins Kinvent: Paving the Way for a Bright Future

To support us in this phase of expansion: acceleration of R&D, as well as international expansion, especially in the US market, Eurazeo is joining our company’s leadership. As a company dedicated to the development of health sectors in France, Eurazeo is taking a minority stake, alongside Athanase Kollias, founding chairman, and existing minority shareholders including Unifund, Sofilaro, BADGE, and Raphaël Varane among others.

Reflecting on the new partnership, Athanase Kollias, President, and founder of Kinvent said, “Our teams are delighted to welcome Eurazeo, a leading investment player, so we can build towards the goal of being the world leader in connected solutions for physiotherapy and sports practitioners together. We are at a structuring stage in our history, in a rapidly expanding market, and have been convinced by the Nov Santé team’s ability to accompany Kinvent’s development, its knowledge of the Health market, and its internal expertise,” 

To achieve our ambitions, we will rely on the health expertise and experience of the Nov Santé team in structuring a rapidly growing company and executing a broad commercial development plan. Arnaud Vincent, Managing Director of the Nov Santé Fund at Eurazeo has commented, “Nearly three years after the fund’s launch and a start on development capital, we are opening a new chapter with our first Growth Equity deal. We are very proud that Kinvent has chosen us as the lead investor. The company’s expertise, its position as a leader and innovator, as well as the quality of its management team convinced the entire Eurazeo team. This investment aligns perfectly with Nov Santé’s strategy to participate in the digitization of a healthcare profession and accelerate the transformation of French and European SMEs,” 

At Kinvent, our mission is to make the most objective, results driven physiotherapy not only possible but accessible to physiotherapy and sports medicine experts everywhere. This transformation will allow us to do just that. We look forward to leveraging this spectacular investment along with the invaluable expertise of our new partners Eurazeo to continue making great strides in physiotherapy innovation as well as maximizing our potential to touch the lives of countless more patients. To learn more, read the press release for this monumental moment in our company’s history here.

[The press talks about us, see the article in The Recursive and Sports Business Journal]